General Archives - Page 2314 of 2367

4 minute read

Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary

July 19, 6:11 PM

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

ALNA

1 minute read

White House Eyes Limited Abortion Health Emergency Declaration

By Benzinga Newsdesk

July 19, 5:27 PM

-Politico

AGRX

3 minute read

The BIG Short: Hedge Fund Is Up 223% In 2022 Shorting This Sector

By AJ Fabino

July 19, 5:15 PM

After a nearly two-year trade that accumulated losses in the nine figures, Coltrane Asset Management’s Mandeep Manku can now revel in the light of being right.

AAPL

1 minute read

Belite Bio Seeks FDA Clearance For Late-Stage Genetic Eye Disease Study

By Ragothaman Srinivasan

July 19, 4:32 PM

Belite Bio (NASDAQ: BLTE) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to support Phase 3 development of its lead asset LBS-008 for treatment of Stargardt Disease (STGD1).

BLTE

1 minute read

Novavax Says FDA Determined That First Lot Of COVID Vaccine Doses Met All Release Specifications And Is Acceptable For Use Under Emergency Use Authorization; Says Expects To Ship Doses To US Government-Designated Distribution Center In Coming Days

By Bill Haddad

July 19, 4:22 PM

-Reuters

NVAX

1 minute read

Honest Company Shares Soar Following Launch On Walmart

By Shivani Kumaresan

July 19, 3:48 PM

Honest Company Inc (NASDAQ:HNST), known as the go-to clean, conscious lifestyle brand, launched in 2012 by Jessica Alba, has expanded…

HNST

1 minute read

White House National Security Adviser John Kirby Says Russia Will Face Additional Sanctions

By Benzinga Newsdesk

July 19, 3:37 PM

-Reuters

RSX

1 minute read

Sorrento Shares Gain Following FDA’s Nod for Initial-Stage Covid-19 Study

By Ragothaman Srinivasan

July 19, 3:20 PM

Sorrento Therapeutics (NASDAQ: SRNE) announced that the U.S. Food and Drug Administration (FDA) has cleared the Phase 1 study of its candidate, STI-1558, in patients with impaired renal and hepatic function.

SRNE